Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedAug 05, 2026
DataAggregated Company Financials
Companies317
  • 7D-4.6%
  • 3M10.4%
  • 1Y43.4%
  • YTD11.3%

Over the last 7 days, the Pharma industry has dropped 4.6%, driven by Eli Lilly declining 8.6%. In the past year, the industry has gained 43%. As for the next few years, earnings are expected to grow by 18% per annum.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 05 Aug 2026US$2.5tUS$429.2bUS$60.0b15.6x42x5.9x
Fri, 03 Jul 2026US$2.5tUS$425.2bUS$65.8b15.4x38.6x6x
Sun, 31 May 2026US$2.4tUS$424.1bUS$66.3b15.4x35.9x5.6x
Tue, 28 Apr 2026US$2.2tUS$408.1bUS$66.8b15.8x32.6x5.3x
Thu, 26 Mar 2026US$2.2tUS$406.2bUS$71.9b16.8x30.6x5.4x
Sat, 21 Feb 2026US$2.4tUS$411.5bUS$73.9b19.6x32.3x5.8x
Mon, 19 Jan 2026US$2.3tUS$402.6bUS$71.5b20.7x31.7x5.6x
Wed, 17 Dec 2025US$2.2tUS$402.8bUS$71.4b20.1x31.5x5.6x
Fri, 14 Nov 2025US$2.1tUS$402.8bUS$71.4b18x29.5x5.2x
Sun, 12 Oct 2025US$1.9tUS$387.6bUS$61.0b19.9x31x4.9x
Tue, 09 Sep 2025US$1.8tUS$387.9bUS$61.0b18.9x29.1x4.6x
Thu, 07 Aug 2025US$1.8tUS$383.7bUS$56.9b18.1x30.8x4.6x
Sat, 05 Jul 2025US$1.7tUS$382.7bUS$61.3b18.3x28.5x4.6x
Mon, 02 Jun 2025US$1.7tUS$382.7bUS$61.2b17.8x27.6x4.4x
Wed, 30 Apr 2025US$1.8tUS$378.6bUS$63.0b17.2x28.6x4.8x
Fri, 28 Mar 2025US$1.8tUS$381.1bUS$41.2b16x44.6x4.8x
Sun, 23 Feb 2025US$1.9tUS$381.1bUS$39.0b18.6x48.6x5x
Tue, 21 Jan 2025US$1.8tUS$369.3bUS$31.2b18.9x56.1x4.7x
Thu, 19 Dec 2024US$1.8tUS$369.4bUS$31.1b17.3x58.1x4.9x
Sat, 16 Nov 2024US$1.8tUS$373.8bUS$30.4b20.1x60.3x4.9x
Mon, 14 Oct 2024US$2.0tUS$364.2bUS$25.3b18.7x80.1x5.6x
Wed, 11 Sep 2024US$2.0tUS$364.1bUS$25.5b18.6x79.3x5.5x
Fri, 09 Aug 2024US$1.9tUS$359.8bUS$21.5b16.2x86.2x5.1x
Sun, 07 Jul 2024US$2.0tUS$357.6bUS$13.8b15.1x141.8x5.5x
Tue, 04 Jun 2024US$1.9tUS$358.3bUS$14.1b16.4x133.6x5.2x
Thu, 02 May 2024US$1.8tUS$361.3bUS$18.4b23.5x99.6x5.1x
Sat, 30 Mar 2024US$1.9tUS$355.3bUS$22.6b19.8x84.4x5.4x
Mon, 26 Feb 2024US$1.9tUS$355.2bUS$24.0b24.1x80x5.4x
Wed, 24 Jan 2024US$1.8tUS$361.7bUS$33.2b26.6x53.1x4.9x
Fri, 22 Dec 2023US$1.6tUS$375.2bUS$33.9b26.6x48.6x4.4x
Sun, 19 Nov 2023US$1.6tUS$375.1bUS$34.0b25.8x48x4.3x
Tue, 17 Oct 2023US$1.7tUS$381.8bUS$43.8b16.9x39.3x4.5x
Thu, 14 Sep 2023US$1.8tUS$381.8bUS$43.9b16.1x40x4.6x
Sat, 12 Aug 2023US$1.8tUS$381.5bUS$43.9b18.7x40.2x4.6x
Price to Earnings Ratio

40.2x


Total Market Cap: US$1.8tTotal Earnings: US$43.9bTotal Revenue: US$381.5bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 54.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.0x which is lower than its 3-year average PE of 54.5x.
  • The 3-year average PS ratio of 5.1x is lower than the industry's current PS ratio of 5.9x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 11% per year over the last three years.
  • Revenues for these companies have grown 4.0% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market4.85%
Healthcare-1.96%
Pharma-4.56%
Pharma-4.56%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
BMY Bristol-Myers SquibbUS$65.893.6%
+US$4.7b		43.7%PE14.5x
TEVA Teva Pharmaceutical IndustriesUS$34.438.7%
+US$3.2b		119.2%PE56.8x
CORT Corcept TherapeuticsUS$109.8016.6%
+US$1.8b		55.9%PE218.7x
PFE PfizerUS$25.410.6%
+US$911.9m		2.7%PE33.4x
JAZZ Jazz PharmaceuticalsUS$261.622.2%
+US$903.5m		147.0%PE18.1x

Latest News

LLY
US$1,115.68
Eli Lilly
7D
-8.6%
1Y
45.7%
JNJ
US$254.93
Johnson & Johnson
7D
-4.4%
1Y
49.3%
PFE
US$25.41
Pfizer
7D
0.6%
1Y
2.7%
CORT
US$109.80
Corcept Therapeutics
7D
16.6%
1Y
55.9%
Analysis Article • 11h

We Think That There Are More Issues For Corcept Therapeutics (NASDAQ:CORT) Than Just Sluggish Earnings

Following the release of a lackluster earnings report from Corcept Therapeutics Incorporated ( NASDAQ:CORT ) the stock...
MRK
US$128.00
Merck
7D
-2.9%
1Y
58.4%
RPRX
US$57.48
Royalty Pharma
7D
-2.9%
1Y
54.8%
Seeking Alpha • 16h

Royalty Pharma: At The Right P/E, I'm In (But Not Here)

Summary Royalty Pharma is a market-leading pharmaceutical royalty company with a unique capital allocation model and a 60% industry share. RPRX offers exposure to blockbuster drug revenues with diversified risk but faces concentration in Vertex and lumpy milestone payments. Despite strong fundamentals and 10%+ expected top line CAGR, the current valuation (11-12x P/E) does not provide sufficient upside. I assign a 'Hold' rating with a $49/share target, requiring a better entry point for a 15% annualized return. Read the full article on Seeking Alpha
JAZZ
US$261.62
Jazz Pharmaceuticals
7D
2.2%
1Y
147.0%
INDV
US$36.50
Indivior Pharmaceuticals
7D
-11.0%
1Y
67.4%
BMY
US$65.89
Bristol-Myers Squibb
7D
3.6%
1Y
43.7%
BHC
US$6.44
Bausch Health Companies
7D
42.5%
1Y
8.4%
TEVA
US$34.43
Teva Pharmaceutical Industries
7D
8.7%
1Y
119.2%
Seeking Alpha • Aug 03

Teva's Re-Rating Still Has Room To Run

Summary Teva Pharmaceutical is undergoing a transformation, shifting its revenue mix toward specialty and innovative drugs, now over $1 billion per quarter. TEVA targets $3.7 billion in specialty/innovative sales for 2026 and aims for operating margins near 30% by 2027, driven by product mix and cost savings. Leverage has dropped below 3x EBITDA, with a goal of 2x by 2027, supported by $2–$2.4 billion free cash flow guidance for 2026. I maintain a Buy rating, as TEVA still trades below sector multiples and further upside is possible if specialty growth and margin targets are met. Read the full article on Seeking Alpha
BIOA
US$11.20
BioAge Labs
7D
-49.5%
1Y
158.7%
MBX
US$70.70
MBX Biosciences
7D
17.7%
1Y
491.6%
ZTS
US$76.04
Zoetis
7D
-1.9%
1Y
-48.0%
Narrative Update • Jul 22

ZTS: Premium Pet Health Portfolio Will Support Post Lawsuit And Guidance Reset

The analyst price target for Zoetis has been lowered, with the model fair value estimate moving from about $124.59 to $114.76, as analysts temper revenue growth assumptions while slightly improving profit margin and applying a lower future P/E multiple in response to a broad series of recent target cuts and more cautious commentary following Q1 results. Analyst Commentary Recent research on Zoetis shows a clear reset in expectations, with most analysts cutting price targets and recalibrating models after a difficult Q1 and updated guidance.
AXSM
US$212.17
Axsome Therapeutics
7D
-6.7%
1Y
105.5%
Narrative Update • Jul 22

AXSM: Alzheimer’s Agitation Launch Will Drive Future CNS Portfolio Upside

Axsome Therapeutics' analyst fair value estimate has been nudged higher from $276.47 to $282.51, as analysts factor in recent price target increases around $300 to $310 that highlight Auvelity's new Alzheimer's disease agitation indication and potential contributions from products like Sunosi and Symbravo. Analyst Commentary Recent Street research on Axsome Therapeutics has focused heavily on Auvelity's new indication in Alzheimer's disease agitation and the contribution of the broader commercial portfolio, with several firms adjusting price targets into the US$300 to US$310 range.
ELVN
US$61.11
Enliven Therapeutics
7D
13.7%
1Y
218.0%